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Abstract
Background: Renal cell carcinoma (RCC) is a cancer of increasing incidence and mortality. Currently, there are no
immunohistochemical prognostic markers for RCCs in routine use. The aim of this study was to examine for the
first time the immunostaining of myosin VI in RCCs as well as its association with E-cadherin and beta-catenin
immunostaining and the prognostic significance of these markers in RCCs.
Methods: Our study population consisted of 152 patients who underwent surgery for RCCs between 1990 and
1999. The tumours were examined with three immunohistochemical markers: myosin VI, E-cadherin and beta-
catenin.
Results: The immunostaining for cytoplasmic myosin VI was common (72%). One-third of the tumours were
immunopositive for nuclear myosin VI. Cytoplasmic myosin VI immunopositivity and nuclear beta-catenin
immunostaining were associated with lower Fuhrman grades (p = 0.04 and p = 0.005, respectively), but not stages.
There was no significant association between myosin VI immunostaining and the histological subtype of RCC.
Nuclear myosin VI was associated with the nuclear expression of beta-catenin. A direct association could also be
proven between membranous E-cadherin and cytoplasmic beta-catenin. Cytoplasmic myosin VI immunostaining
was a marker of poorer prognosis in multivariate Cox regression model adjusted with stage and Fuhrman grade
with hazard ratio 2.4 (95% confidence interval 1.1 to 5.0 with p = 0.024).
Conclusions: Cytoplasmic myosin VI immunopositivity and nuclear beta-catenin immunostaining were associated
with lower Fuhrman grades, and there was a strong positive relationship between E-cadherin immunostaining and
beta-catenin immunostaining in RCCs. Cytoplasmic myosin VI immunostaining was associated with poorer
prognosis in RCCs.
Background
Renal cell carcinoma (RCC) is a cancer of increasing inci-
dence and mortality [1]. By diagnosis, up to one-third of
patients already have a metastasised disease and half of
the remaining patients will suffer a recurrence after cura-
tive treatment [2]. The behaviour of RCC can be difficult
to predict even though there are many well-known prog-
nostic factors for the disease. Myosins are a large family
of molecular motor proteins and their immunoexpres-
sion has previously been demonstrated in variety of
epithelial cancers including RCCs [3-5]. Myosin VI is one
of the so-called unconventional myosins that moves in a
reverse direction when compared to the other known
myosins, i.e. it moves from the plasma membrane into
the cell and away from the surface of internal organelles
such as the Golgi complex. Myosin VI plays a role both
in transporting and anchoring the cells and takes part in
a wide range of cellular processes such as endocytosis,
exocytosis, cell migration, cell division and cytokinesis
[3,6]. Furthermore, myosin VI is linked to E-cadherin
and beta-catenin in ovarian cancer [7].
One of the key processes in developing metastasised
disease is a loss of cellular adhesion [8]. E-cadherin, a
member of the adhesion molecule family of cadherins,
mediates predominantly cell-cell adhesion in epithelium
and epithelial tumours. It is a tumour suppressor, the
loss of which is known to worsen the prognosis of many
cancers. The whole function of E-cadherin is not yet
well understood but it might influence the transcription
of target genes [9-15]. Transmembranic glycoprotein E-
cadherin interacts with the cytoskeleton via intracellular
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damaged by the loss of E-cadherin expression or
changes in catenin expression, which leads to the loss of
cadherin function. The cadherin-catenin complex also
influences migration and modifies cell growth and the
survival of neoplastic cells [8]. In addition, beta-catenin,
a member of the catenin family, participates in signal
transduction [16,17].
There are no current immunohistochemical prognostic
markers for RCCs in routine use. In this era of new treat-
ment possibilities there remains a need for better prog-
nostic tools to plan the treatment and follow-up of RCC
patients. The purpose of this study was to examine for
the first time the immunostaining of myosin VI in RCCs
and to investigate the prognostic potential of immunos-
taining myosin VI, E-cadherin and beta-catenin in RCCs.
Methods
Patients
The study population has been described in detail earlier
[18]. Briefly, the retrospective study population consisted
of 152 patients who underwent surgery for RCCs
b e t w e e n1 9 9 0a n d1 9 9 9a tt h eO u l uU n i v e r s i t yH o s p i t a l
in Finland. Seven patients (5%) were operated by resec-
tion and 145 (95%) by radical nephrectomy. The
patients’ follow-up details were collected from patient
records. Follow-up was completed in all cases. The
research plan was approved by the local ethical board.
The stage of the tumours was assigned using the TNM
(tumour-node-metastasis) staging of RCCs [19].
Tumour samples
The tumour samples were fixed in 10% buffered forma-
lin and embedded in paraffin. Histological diagnosis was
confirmed by reviewing haematoxylin and eosin (H &
E)-stained original sections. The tumours were reclassi-
fied and graded according to the WHO classification
[20]. The most representative block was selected to
reconstruct a multitissue block, which was used for
immunohistochemistry.
Immunostaining procedure
The immunoexpression of myosin VI, E-cadherin and
beta-catenin was analysed using monoclonal antibodies.
The antibodies used in the study were monoclonal anti-
myosin VI (Sigma, St. Louis, MO, USA) in a dilution of
1:250, mouse anti-E-cadherin (Zymed Laboratories, San
Francisco, CA, USA) in a dilution of 1:300 and anti-
beta-catenin (BD Biosciences, San Jose, CA, USA) in a
dilution of 1:200. For antigen retrieval, the sections were
incubated in 0.01 M citrate buffer (pH 6) twice for 5
min and boiled in a microwave oven to enhance immu-
noreactivity. The sections were cooled for 15 min in
0.05 M Tris buffered saline (TBS) (pH 7.5) and washed
twice in PBS. Endogenous peroxidise activity was elimi-
nated by incubation in 5% hydrogen peroxide and abso-
lute methanol. Bound antibodies were visualised using
an EnVision+ System-HRP (DakoCytomation, Glostrup,
Denmark).
Immunohistochemical evaluation of the markers
Immunohistochemical staining was evaluated simulta-
neously by three observers (HR, PH and SK) and a con-
sensus was reached. Immunostaining for cytoplasmic
myosin VI and membranous E-cadherin was classified
as follows: negative and weak positive were considered
negative and moderate and strong positive were consid-
ered positive. Immunostaining was classified negative
and positive for nuclear myosin VI, E-cadherin and
beta-catein as well as cytoplasmic beta-catein. The result
was considered positive when any staining was detected.
Statistical analyses
SPSS for Windows 15 (Chicago, IL, USA) was used for
statistical analyses. The chi - s q u a r e dt e s to rF i s h e r ’s
exact test was used to study associations between differ-
ent variables. Survival was analysed with the Kaplan-
Meier curve and significance with the log rank test. The
Cox regression multivariate model was used for multi-
variate analysis using Fuhrman grade, stage, tumour dia-
meter, age or gender as adjusting factors.
Results
Patient demographics and staining correlation with
clinical parameters
At the time of diagnosis, the median age of patients was
63 years (range 29-86 years). Seventy-seven (51%)
patients were women and 75 (49%) men. The median
follow-up time was 90 months (range 0-209 months).
During follow-up, 44 (29%) patients died because of
RCCs, 40 (26%) died of other causes and 68 (45%)
patients were still alive. The distribution of tumour
classes (TNM classification), clinical stages, tumour
grades and the histological subtype of the RCC in com-
parison to the immunostaining pattern for myosin VI,
beta-catenin and E-cadherin are described in Table 1,
Table 2 and Table 3, respectively.
Myosin VI immunostaining in RCCs
Cytoplasmic myosin VI was positive in 104 (72%) and
negative in 41 (28%) cases. Cytoplasmic myosin VI
immunopositivity was associated with lower Fuhrman
grades (p = 0.04) but not stages (Table 1). In univariate
survival analysis, the patients with RCCs expressing
cytoplasmic myosin VI had a tendency for lower RCC-
specific survival, but this was not significant (p =0 . 2 7
for ten-year RCC-specific survival) (Figure 1, Table 4).
However, adjusting Cox regression model with the
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grade, cytoplasmic myosin VI immunostaining was a
prognostic marker with hazard ratio (HR) 2.4 (95% con-
fidence interval (CI) 1.1 to 5.0 with p = 0.024). When
tumour diameter was retained in the model, HR for
cytoplasmic myosin VI was 3.5 (95% CI 1.5 to 7.9) with
p = 0.003. Further adjusting the model with age or gen-
der, which were not statistically significant factors, the
HR for cytoplasmic myosin VI was 2.4 (p = 0.025) and
2.4 (p = 0.025), respectively. The mean survival times
for subjects with Fuhrman grade II cytoplasmic myosin
VI immunonegative and immunopositive tumours died
of RCC during follow-up were 101 (standard deviation
(SD) ± 71) and 52 (SD ± 47) months, respectively. None
of the patients with Fuhrman grade I tumours died of
RCC during the follow-up. Immunostaining for nuclear
myosin VI was observed in 51 (35%) cases. Myosin VI
immunostaining was not associated with the histological
subtype of RCCs (Table 1). Nuclear immunostaining for
myosin VI was not a prognostic factor in RCC-specific
survival (p = 0.9) (Table 4) and did not correlate with
Fuhrman grades or stages (Table 1).
Beta-catenin immunostaining in RCCs
Nuclear staining for beta-catenin was seen in 65 (44%)
cases and cytoplasmic staining in 13 (9%). Nuclear beta-
catenin immunoexpression was associated with lower
Fuhrman grades (p = 0.005) but not stages (Table 2).
Cytoplasmic staining for beta-catenin was not associated
with stages or grades (Table 2). There was no relation-
ship between the histological subtype of RCCs and
immunoreactivity for beta-catenin. For RCC-specific
survival beta-catenin immunoexpression had no prog-
nostic significance (Table 4).
E-cadherin immunostaining in RCCs
Membranous staining for E-cadherin was observed in 14
(9%) cases and nuclear staining in 59 (40%). Membra-
nous staining for E-cadherin was associated with histo-
logical subtype (p < 0.001). It was more common in
Table 1 Associations between immunostaining for
myosin VI and tumour class, stage, grade and
histological subtype of RCC.
Cytoplasmic
myosin VI
Nuclear myosin VI
positive negative positive negative
Tumour class (T)
1 (n = 71) 54 (76%) 17 (24%) 25 (35%) 46 (65%)
2 (n = 11) 6 (55%) 5 (45%) 3 (27%) 8 (73%)
3 (n = 57) 41 (72%) 16 (28%) 20 (35%) 37 (65%)
4 (n = 6) 3 (50%) 3 (50%) 3 (50%) 3 (50%)
Stage
I (n = 66) 50 (76%) 16 (24%) 23 (35%) 43 (65%)
II (n = 11) 6 (55%) 5 (45%) 3 (27%) 8 (73%)
III (n = 49) 35 (71%) 14 (29%) 19 (39%) 30 (61%)
IV (n = 19) 13 (68%) 6 (32%) 6 (32%) 13 (68%)
Grade
I (n = 5) 5 (100%) 0 (0%) 1 (20%) 4 (80%)
II (n = 79) 59 (75%) 20 (25%) 31 (39%) 48 (61%)
III (n = 38) 28 (74%) 10 (26%) 10 (26%) 28 (74%)
IV (n = 21) 10 (48%) 11 (52%) 8 (38%) 13 (62%)
Histological subtype of
RCC
clear cell (n = 128) 89 (70%) 39 (30%) 46 (36%) 82 (64%)
papillary (n = 10) 9 (90%) 1 (10%) 2 (20%) 8 (80%)
chromophobic (n = 5) 4 (80%) 1 (20%) 2 (40%) 3 (60%)
undifferentiated (n = 2) 2 (100%) 0 (0%) 1 (50%) 1 (50%)
Number of patients with different characteristics and respective cytoplasmic
and nuclear myosin VI immunostaining are presented.
Table 2 Associations between immunostaining for beta-
catenin and tumour class, stage, grade and histological
subtype of RCC.
Cytoplasmic beta-
catenin
Nuclear beta-
catenin
positive negative positive negative
Tumour class (T)
1 (n = 71) 5 (7%) 66 (93%) 36 (51%) 35 (49%)
2 (n = 11) 2 (18%) 9 (82%) 2 (18%) 9 (82%)
3 (n = 59) 6 (10%) 53 (90%) 24 (41%) 35 (59%)
4 (n = 6) 0 (0%) 6 (100%) 3 (50%) 3 (50%)
Stage
I (n = 66) 5 (8%) 61 (92%) 34 (52%) 32 (48%)
II (n = 11) 2 (18%) 9 (82%) 2 (18%) 9 (82%)
III (n = 51) 5 (10%) 46 (90%) 21 (41%) 30 (59%)
IV (n = 19) 1 (5%) 18 (95%) 8 (42%) 11 (58%)
Grade
I (n = 5) 0 (0%) 5 (100%) 2 (40%) 3 (60%)
II (n = 80) 6 (7%) 74 (93%) 46 (58%) 34 (42%)
III (n = 38) 2 (5%) 36 (95%) 9 (24%) 29 (76%)
IV (n = 22) 4 (18%) 18 (82%) 8 (36%) 14 (64%)
Histological subtype of
RCC
clear cell (n = 130) 10 (8%) 120 (92%) 58 (45%) 72 (55%)
papillary (n = 10) 1 (10%) 9 (90%) 4 (40%) 6 (60%)
chromophobic (n = 5) 1 (20%) 4 (80%) 3 (60%) 2 (40%)
undifferentiated (n = 2) 1 (50%) 1 (50%) 0 (0%) 2 (100%)
Number of patients with different characteristics and respective cytoplasmic
and nuclear beta-catenin immunostaining are presented.
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cell RCCs, whereas no positivity was observed in papil-
lary subtypes (Table 3). Nuclear E-cadherin immunoex-
pression and the histological subtype of RCCs were
unassociated (Table 3). Neither stage nor differentiation
was associated with the E-cadherin staining pattern
(Table 3). The nuclear or membranous expression of
E-cadherin was not a prognostic factor for RCC-specific
survival (Table 4).
Association between myosin VI, beta-catenin and
E-cadherin immunostaining in RCCs
Nuclear myosin VI was associated with beta-catenin
immunostaining (p = 0.008). The relationship between
nuclear myosin VI and E-cadherin and cytoplasmic myo-
sin VI and membranous E-cadherin were not significant
(p =0 . 0 9a n dp = 0.07, respectively). Nuclear staining
patterns for E-cadherin and beta-catenin (p < 0.001) and
membranous E-cadherin and cytoplasmic beta-catenin (p
= 0.02) were associated with each other. The associations
between E-cadherin, beta-catenin and myosin VI immu-
nostaining are represented in Table 5.
Discussion
This was the first study characterising the expression of
myosin VI in RCCs. Here, cytoplasmic myosin VI
immunopositivity was associated with the lower Fuhr-
man grades of RCCs, but in multivariate Cox regression
model it was also a marker of poorer prognosis. The
immunoexpression of myosin VI has been demonstrated
in prostatic adenocarcinoma [21,22]. There is also evi-
dence that links myosin VI to the migration of human
Table 3 Associations between immunostaining for
E-cadherin and tumour class, stage, grade and
histological subtype of RCC.
Membranous
E-cadherin
Nuclear E-cadherin
positive negative positive negative
Tumour class (T)
1 (n = 72) 7 (10%) 65 (90%) 34 (47%) 38 (53%)
2 (n = 11) 1 (9%) 10 (91%) 5 (45%) 6 (55%)
3 (n = 59) 5 (8%) 54 (92%) 17 (29%) 42 (71%)
4 (n = 6) 1 (17%) 5 (83%) 3 (50%) 3 (50%)
Stage
I (n = 67) 6 (9%) 61 (91%) 32 (48%) 35 (52%)
II (n = 11) 1 (9%) 10 (91%) 5 (45%) 6 (55%)
III (n = 51) 5 (10%) 46 (90%) 13 (25%) 38 (75%)
IV (n = 19) 2 (10%) 17 (90%) 9 (47%) 10 (53%)
Grade
I (n = 5) 0 (0%) 5 (100%) 1 (20%) 4 (80%)
II (n = 81) 4 (5%) 77 (95%) 38 (47%) 43 (53%)
III (n = 38) 5 (13%) 33 (87%) 14 (37%) 24 (63%)
IV (n = 22) 3 (14%) 19 (86%) 6 (27%) 16 (73%)
Histological subtype of
RCC
clear cell (n = 131) 8 (6%) 123 (94%) 52 (40%) 79 (60%)
papillary (n = 10) 0 (0%) 10 (100%) 6 (60%) 4 (40%)
chromophobic (n = 5) 4 (80%) 1 (20%) 1 (20%) 4 (80%)
undifferentiated (n = 2) 2 (100%) 0 (0%) 0 (0%) 2 (100%)
Number of patients with different characteristics and respective membranous
and nuclear E-cadherin immunostaining are presented.
Figure 1 Cytoplasmic myosin VI as a prognostic factor in ten-year RCC-specific survival. Kaplan-Meier curve of 145 patients. p = 0.27.
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Marker Immunostaining result Mean survival (months) 95% CI p-value
Cytoplasmic myosin VI negative 162 137-187 0.3
positive 146 128-163
Nuclear myosin VI negative 151 134-169 0.9
positive 141 118-164
Membranous E-cadherin negative 153 138-168 0.3
positive 113 73-152
Nuclear E-cadherin negative 144 124-164 0.4
positive 158 137-179
Cytoplasmic beta-catenin negative 152 137-167 0.5
positive 128 81-174
Nuclear beta-catenin negative 143 124-163 0.3
positive 157 136-178
P values presented were produced with the log rank test. CI, confidence interval.
Table 5 Association between immunostaining for myosin VI, E-cadherin and beta-catenin.
Nuclear myosin VI p-value
negative positive
Nuclear beta-catenin negative 59 (74%) 21 (26%)
positive 33 (52%) 30 (48%) 0.008
Cytoplasmic myosin VI
Negative positive
Cytoplasmic beta-catenin negative 38 (29%) 92 (71%)
positive 3 (23%) 10 (77%) 0.8*
Nuclear myosin VI
negative positive
Nuclear E-cadherin negative 61 (70%) 26 (30%)
positive 32 (56%) 25 (44%) 0.09
Cytoplasmic myosin VI
negative positive
Membranous E-cadherin negative 40 (31%) 90 (69%)
positive 1 (7%) 13 (93%) 0.07*
Nuclear beta-catenin
negative positive
Nuclear E-cadherin negative 66 (75%) 22 (25%)
positive 16 (27%) 43 (73%) <0.001
Cytoplasmic beta-catenin
negative positive
Membranous E-cadherin negative 124 (93%) 9 (7%)
positive 10 (71%) 4 (29%) 0.02*
P values presented were produced with the chi-squared test or Fisher’s exact test (*).
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myosin VI expression has been associated with the
aggressive behaviour of the tumour [24]. In our study,
cytoplasmic myosin VI immunostaining was not a statis-
tically significant prognostic factor according to log rank
test. However, in multivariate Cox regression model
adjusted with the known prognostic factors of RCCs,
stage and Fuhrman grade, cytoplasmic myosin VI immu-
nostaining was a prognostic marker for RCC specific
survival. This means, that confounding factors affecting
the results of log rank test were present, which could be
reduced in Cox regression model. Noteworthy, the HR
for cytoplasmic myosin VI immunostaining was
increased also when tumour diameter, age or gender
was retained to the model. Despite the association of
cytoplasmic myosin VI immunopositivity with lower
Fuhrman grades, the mean survival times for subjects
with cytoplasmic myosin VI immunopositive Fuhrman
grade II tumours died of RCC during follow-up were
shorter in comparison with subjects with cytoplasmic
myosin VI immunonegative tumours. So cytoplasmic
myosin VI immunopositivity seems to have prognostic
potential also within Fuhrman grade II tumours but not
only within poorly differentiated tumours.
It has been reported that membranous beta-catenin
immunoexpression is downregulated in conventional
RCCs with low nuclear grades but higher in papillary
and chromophobic carcinomas than conventional RCCs
[25]. In our study, nuclear beta-catenin immunostaining
was more frequently detected in cases with lower Fuhr-
man grades, but we found no prognostic significance of
beta-catenin immunostaining in RCCs. Furthermore, we
detected no differences in beta-catenin immunoexpres-
sion patterns between the different histological subtypes
of RCCs.
According to our study, nuclear E-cadherin expression
is neither an independent prognostic factor in RCC-spe-
cific survival nor associated with the nuclear grade of
the tumour. Nuclear E-cadherin has previously been
demonstrated to be associated with better prognosis of
RCCs [15], and there has also been a reported downre-
gulation of E-cadherin expression in clear cell RCCs
[26]. In our study population, we could not prove the
prognostic importance of E-cadherin that had previously
been shown in smaller study populations and with
shorter follow-up times. In previous studies, nuclear E-
cadherin expression was detected only in clear cell
RCCs [15]. In our study, some nuclear positivity was
also demonstrated in papillary and chromophobic
carcinomas.
According to our study, nuclear myosin VI is asso-
ciated with beta-catenin but there is no relationship
between myosin and E-cadherin in RCCs. Myosin VI is
linked to E-cadherin and beta-catenin and participates
in border cell migration where it stabilises the E-cad-
herin-beta-catenin cell adhesion complex [7]. Myosin VI
is a cytoplasmic protein and the significance of nuclear
myosin VI immunostaining is unknown. Beta-catenin,
however, can be detected in the nucleus in various car-
cinomas [27-30]. Nuclear myosin VI could be a regulat-
ing factor for beta-catenin or a co-worker. The
association between myosin VI and beta-catenin might
also suggest that beta-catenin provides a molecular
mechanism for signal transduction from the cytoplasm
to the nucleus of the cell, thereby also influencing myo-
sin VI gene expression. Beta-catenin plays a role in the
Wnt (wingless type) pathway where the multiprotein
destruction complex which involves APC (adenomatous
polyposis coli) influences the phosphorylation and
unphosphorylation of beta-catenin and has been demon-
strated to lead to the transcription and expression of
oncogenes such as c-myc and c-jun [16,17]. Beta-catenin
has also been reported to be capable of regulating gene
expression by the direct interaction with transcription
factors such as LEF-1 (lymphoid enhancer-binding fac-
tor), providing a molecular mechanism for a signal
transmission from cell-adhesion components to the
nucleus [16]. In our study, we also found a positive rela-
tionship between nuclear E-cadherin and beta-catenin
immunostaining, which has previously been detected in
gastrointestinal carcinomas [15,31,32].
Conclusions
Our findings were that in RCCs there is immunoexpres-
sion of myosin VI in cytoplasm and nucleus, and cytoplas-
mic myosin VI is an independent prognostic factor in
RCC-specific survival. In the future, myosin VI may have
use as a prognostic marker of RCCs. Cytoplasmic myosin
VI immunopositivity and nuclear beta-catenin immunos-
taining were associated with lower Fuhrman grades but
not stages. Nuclear myosin VI and beta-catenin immu-
noexpression are associated with each other. Nuclear E-
cadherin and beta-catenin immunostaining patterns are
also positively related together. The discrepancy with pre-
vious studies concerning the prognostic importance of
nuclear E-cadherin in RCCs might be because of different
study populations and follow-up times.
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